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A high-performance liquid chromatographic method employing pre-column derivatization with 
o-phthalaldehyde (OPA) and 2-mercaptoacetic acid was developed for the determination of apramycin, 
an aminoglycoside antibiotic used in veterinary medicine, in the oral soluble powder form. The 
chromatographic separation was done by ion-pair HPLC using a C18 reversed-phase column, Synergy 
Hydro (150 mm x 4.6 mm x 4 μm) and mobile phase composed of 0.005 mol/L sodium octanosulfonate 
in a mixture of acetonitrile: water: acetic acid (45:55:2) (v/v/v) with a flow rate of 1.0 mL/min; the UV 
detector was operated at 332 nm. The developed method was validated according to official compendia 
guidelines, having demonstrated robustness, selectivity and linearity for the concentration range of 0.02 
to 0.05 mg/mL, precision (with RSD < 2.0% both for intra and inter-day precision) accuracy (average 
recuperation of 99.33%) and detectivity (quantification and detection limits of 0.08 and 0.02 μg/mL, 
respectively). Three batches of commercial apramycin oral soluble powder were analyzed by both the 
proposed method and the official microbiological method, where all the results obtained were in the 
acceptable range (95% to 105% of labeled value of apramycin). Both methods were statistically compared 
by the t test, which yielded no significant differences (α = 0.05) thereby confirming the equivalence of 
the methods.
Uniterms: Apramycin. HPLC. Microbiological Assay. Pre-column Derivatization. OPA.
Foi desenvolvido um método por cromatografia líquida alta eficiência empregando derivatização pré-
coluna com o-ftalaldeído (OPA) e ácido mercaptoacético para determinação de apramicina, um antibiótico 
aminoglicosídeo de uso veterinário, em pó oral solúvel. A separação cromatográfica foi feita por fase 
reversa com pareamento iônico utilizando-se coluna Synergy Hydro C18 (150 x 4,6 mm x 4 µm) e fase 
móvel composta por octanossulfonato de sódio 0,005 mol/L em mistura de acetonitrila:água:ácido acético 
nas proporções 45:55:2 (v/v/v), numa vazão de 1.0 mL/min; efetuou-se detecção por UV a 332 nm. 
O método foi validado de acordo com os compêndios oficiais e demonstrou robustez, seletividade, 
linearidade na faixa de 0,02 a 0,05 mg/mL, precisão (com DPR < 2,0% tanto para a precisão intra-dia 
quanto para a precisão inter-dia), exatidão (recuperação média de 99,33%) e detectabilidade (limite 
de quantificação e de detecção iguais a 0,08 e 0,02 µg/mL, respectivamente). Analisaram-se 3 lotes 
de apramicina pó oral solúvel pelo método proposto e pelo método microbiológico oficial e todos os 
resultados obtidos estavam dentro do limite de aceitação (95%-105% valor rotulado de apramicina). 
Ambos os métodos foram comparados estatisticamente pelo teste t, não sendo encontradas diferenças 
significativas entre eles para α=0,05, sendo os dois equivalentes.
Unitermos: Apramicina. CLAE. Doseamento Microbiológico. Derivatização pré-coluna. OPA.
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INTRODUCTION
Apramycin is an aminoglycoside antibiotic produ-
ced by a strain of Streptomyces tenebrarius. It is also called 
nebramycin factor-2 and is characterized by a 4-amino-4-
deoxy-D-glucose moiety, a glycosidic linkage 1-1’ and an 
octadiose, which forms a rigid bicyclic system, as depicted 
in Figure 1 (Walton, 1978; Tatsuta et al., 1984).
Its mechanism of action is based on protein synthesis 
inhibition both in vivo and in vitro. Apramycin is employed 
in veterinary medicine in injectable, premix or oral soluble 
powder forms, against infections caused by Gram-negative 
microorganisms (colibacilosis, salmonellosis, bacterial 
enteritis) in domestic birds, swine and calves (Perzynski 
et al., 1979; EMEA, 2008).
Akin to other aminoglycosides, apramycin also 
presents ototoxicity and nephrotoxicity as undesired side 
effects, a worrying aspect if the possibility of residue oc-
currence in the tissues of animals destined for slaughter 
is considered. Besides the determination of apramycin 
residues in food of animal sources, rigorous control of its 
assay in pharmaceutical preparations is required (Macneil, 
Ellis, 1995; Zhang et al., 2007).
British Pharmacopoeia is the only official compen-
dium that describes apramycin (bulk pharmaceutical and 
its preparations), and recommends the microbiological 
turbidimetric assay to determine its potency (BP (Vete-
rinary), 2008). Although microbiological methods are 
the main choice for determining the potency of several 
antibiotics, they are laborious and time-consuming tech-
niques, with lesser precision and accuracy compared to 
physico-chemical methods, particularly those employing 
high performance liquid chromatography (HPLC), which 
is more accurate, precise, sensitive, specific and faster for 
obtaining results (Isoherranen, Soback, 1999).
HPLC has been successfully employed in the analy-
sis of several aminoglycosides using pre- or post-column 
derivatization techniques, since they lack chromophore or 
fluorophore groups in their structure. In the specific case 
of apramycin, there are few published chemical methods 
by HPLC involving biological or animal food samples, as 
described by Sweeney and Coleman (1998) and Zhang et 
al.(2007), respectively.
Considering the several advantages offered by 
HPLC, the need for analytical methods to assure the 
efficacy and safety of apramycin pharmaceutical formu-
lations, particularly in terms of potency and purity, as well 
as the absence of official physico-chemical methods for 
its quantification, the aim of this work was to develop and 
validate a new method for apramycin determination in oral 
soluble powder employing high performance liquid chro-
matography, and to compare the proposed method with the 
official microbiological turbidimetric assay.
MATERIAL AND METHODS
Instrumentation and chromatographic parameters
LC System - The HPLC system consisted of a TSP 
Spectra System equipped with degasser model SCM 1000, 
binary pump model P200, autosampler model AS3000, 
UV/Vis detector Model UV 2000 and fluorescence de-
tector Model FL 3000. The system was controlled by 
an EasyChrom® data station. The detection was initially 
done by a fluorescence detector with excitation wave-
length set at 230 nm and emission wavelength at 389 nm. 
UV detection was adopted later with wavelength set at 
332 nm. The mobile phase chosen after method optimiza-
tion was composed of 0.005 mol/L sodium octanosulfona-
te in a mixture of acetonitrile: water: acetic acid (45:55:2) 
(v/v/v) with a flow rate of 1.0 mL/min; injection volume 
was 50 µL.
LC Columns - Gemini C18, 250 mm x 4.6 mm x 
5 µm, Synergy Fusion C18 250 mm x 4.6 mm x 4 µm and 
Synergy Hydro C18, 150 mm x 4.6 mm x 4 µm, with the 
latter comprising the chosen column after optimization 
tests.
Spectrophotometers - UV/Visible Spectrophotome-
ter Unicam, model Helyos Alpha and Visible Spectropho-
tometer Unicam, model Helyos €.
Materials and reagents
Apramycin working standard was supplied by Eli 
Lilly and had a potency of 873.3 µg/mg where the tobra-
mycin reference standard was from the USP, lot LOB30. 
Three batches of apramycin oral soluble powder 
with labeled value of 44.4 g/ 100 g were supplied by Eli 
Lilly.
The test microorganism used, Salmonella chole-
rasuis ATCC 13311, was supplied by the Adolfo Lutz 
Institute.
FIGURE 1 - Apramycin Chemical Structure
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The following reagents were used: purified water 
from a Milli-Q® apparatus; HPLC grade acetonitrile from 
J.T.Baker; methanol, isopropanol, acetic acid, 1-octa-
nossulfonic sodium salt, 2-mercaptoacetic acid, sodium 
chloride, potassium dihydrogen phosphate and potassium 
hydrogen phosphate, sodium and potassium hydroxide, 
also from J.T. Baker, analytical grade; 2-mercaptoetha-
nol and o-phthalaldehyde (OPA), from Sigma Aldrich, 
analytical grade; boric acid, analytical grade, from Vetec; 
meat and yeast extracts, peptone dextrose and casein-soy 
broth, supplied by Difco.
Method development and validation
·	 Borate Buffer pH 10.4 – Solution prepared as des-
cribed in the BP 2008
·	 Borate Buffer pH 9.5 – Solution prepared according 
to Zhang et al. (2007)
·	 OPA Derivatization Solution I – Solution prepared 
according to Zhang et al. (2007)
·	 OPA Derivatization Solution II – Solution prepared 
as described in the BP 2008 and in USP 32
·	 Apramycin Test Solution – a stock solution of 
0.2 mg/mL apramycin working standard in water 
was prepared and subsequently derivatized.
·	 Tobramycin Test Solution – a stock solution of 
0.2 mg/mL tobramycin reference standard in water 
was prepared, and subsequently derivatized.
·	 Apramycin Working Solutions for Linearity – Six 
apramycin working standard solutions were prepa-
red such that after their submission to derivatization 
the following concentrations were obtained: 0.020, 
0.026, 0.032, 0.034, 0.040 and 0.046 mg/mL cor-
responding, respectively, to 60%, 75%, 90%, 100%, 
115% and 130% of theoretical final concentration 
of apramycin after sample preparation. The 100% 
apramycin working solution was also used in the 
robustness, precision and the quantification and 
detection limits evaluations (in this last case, after 
successive dilutions in water).
·	 Apramycin Solutions for Selectivity – Four apra-
mycin solutions at a concentration of 0.2 mg/mL 
were individually submitted to different forced 
degradation conditions for two hours: acid and alka-
line hydrolysis (with 0.1 mol/L HCl and 0.1 mol/L 
NaOH, respectively), as well as thermal (in water 
bath at 100°C) and oxidative stress (3% H2O2 
aqueous solution). Four excipient solutions of so-
dium bicarbonate (oral soluble powder excipient) at 
a theoretical concentration of 0.55 mg/mL were also 
submitted to the same forced degradation conditions. 
After the exposure period, each solution was deriva-
tized as described below. In the specific case of acid 
and alkaline hydrolysis, solution neutralization was 
done before the mentioned procedure.
·	 Apramycin Working Solutions for Accuracy – The 
recuperation technique was employed to evaluate 
accuracy. Initially, a 1.1 mg/mL sodium bicarbo-
nate solution was prepared. Known concentrations 
of apramycin working standard were then added 
to give, after the derivatization procedure, three 
concentration levels (0.032 mg/mL; 0.040 mg/mL 
and 0.046 mg/mL) where each level was prepared 
in triplicate.
Apramycin assay by HPLC method
Samples of each batch of soluble oral powder were 
prepared in triplicate in such a way that the theoretical 
apramycin concentration for each sample, after derivati-
zation, was 0.034 mg/mL. The linear equation obtained 
from the calibration curve (Apramycin Peak area versus 
Apramycin Concentration) was used to calculate the assay, 
considering sample dilutions. 
Derivatization procedure
Volumes of 10.0 mL and 1.0 mL of OPA I or OPA 
II derivatization solution were added to a 50 mL actinic 
volumetric flask. After mixing, the volume was completed 
with water, and the solution left to rest for 60 minutes. The 
solution was then filtered through a Millex® 0.45 µm into a 
vial, 50 µL of which was injected into the HPLC system. In 
the selectivity tests with tobramycin, 10.0 mL of apramy-
cin, and 10.0 mL of tobramycin test solution, were added 
to a 50 mL actinic volumetric flask, where derivatization 
was done according to the procedure outlined above. Blank 
solution preparation consisted only of OPA derivatization 
solution and the diluent - water.
Apramycin turbidimetric assay
Samples of each batch of soluble oral powder were 
prepared in triplicate and submitted to microbiological tur-
bidimetric assay according to BP 2008 guidelines, with the 
exception of culture medium (medium C was employed, 
instead of the recommended medium H) and the assay 
design (5 x 1 model was adopted, instead of 3 x 3). The 
potency of apramycin was calculated by a linear equation 
obtained from the calibration curve % Transmittance ver-
sus Log Apramycin Concentration, with the appropriate 
transformations while considering sample dilutions.
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RESULTS AND DISCUSSION
Method Development
Apramycin is a highly polar and hydrophilic com-
pound (Martindale, 2007) and similar to other amino-
glycosides, also lacks chromophore or fluorophore. These 
properties justify the use of water as diluent, ion-pairing 
reversed phase chromatography, and of the derivatization 
technique, which was performed with o-phthalaldehyde 
(OPA) in the presence of a thiol, because of several advan-
tages: OPA has no native fluorescence, is not hazardous, is 
low cost, reacts readily at room temperature and is stable 
in aqueous solutions with pH < 11.5. (Fabre et al., 1989; 
Caturla, Cusido, 1992; Dorresteijn et al., 1996; Isoherra-
nen, Soback, 1999; Stead, 2000; Zhang et al., 2007).
Considering these advantages and based on the 
apramycin determination carried out by Sweeney and 
Coleman and Zhang et al., the following chromatographic 
conditions were adopted to initiate method development: 
pre-column derivatization with OPA in the presence of 
2-mercaptoethanol with reaction time of 35 minutes; 
reversed phase separation with a Gemini C18 column of 
250 mm x 4.5 mm x 5 µm; mobile phase composed of 
40% acetonitrile and 60% aqueous solution composed of 
acetic acid and sodium octanosulfonate as an ion pairing 
reagent, at a flow rate of 1.0 mL/min; injection volume of 
50 µL; fluorescence detection with excitation at 230 nm 
and emission at 390 nm.
Under these conditions, the apramycin peak was 
eluted at about 22 minutes, with resolution of 1.76 and 
tailing factor of 1.97. Subsequently, modifications were 
made in order to decrease peak retention time and improve 
performance of the chromatographic method. The best 
results were attained with the addition of 5% more acetoni-
trile to the mobile phase and with the use of a reduced size 
Synergy Hydro C18 column (150 mm x 4.6 mm x 4 µm), 
which supplied an apramycin peak with resolution of 
2.76, tailing factor of 1.44 and retention time of about 11 
minutes.
Since the apramycin peak was in fact due to isoindol 
derivative from the complete reaction of its four primary 
amines with OPA in the presence of 2-mercaptoethanol, 
the next step was to improve apramycin-OPA reaction 
conditions in order to assure complete reaction between 
them, with formation of a stable derivative in a shorter 
period of time. Modifications were made concerning the 
type of thiol and the OPA concentration employed.
When a small chain thiol is employed, such as 
2-mercaptoethanol, the derivative decomposition is favo-
red, whereas the use of a longer chain thiol provides more 
stability to the derivative, as is the case with mercaptoace-
tic acid, which also allows UV detection of the derivative 
(Weigand, Coombes, 1983; Claes, Busson, Vanderhaeghe, 
1984; Albracht, 1987).
A comparative stability test was carried out with 
an apramycin test solution, derivatized in the presence 
of 2-mercaptoethanol with fluorescence detection (initial 
conditions) and with another in the presence of mercap-
toacetic acid with UV detection at 332 nm (maximum 
wavelength absorption obtained in a preliminary test). 
Both solutions were repeatedly injected at intervals of 
15 minutes, from 30 minutes of reaction to 5 hours. The 
results obtained were plotted on the graph Apramycin 
peak Area versus Reaction Time shown in Figure 2. It 
was confirmed that, the derivative formed in the presen-
ce of 2-mercaptoethanol, rapidly self-degrades whereas 
the other formed in the presence of mercaptoacetic acid 
was more stable. Therefore, this second condition was 
adopted.
Concerning OPA concentration, this needed to be 
higher than the theoretical quantity in order to assure its 
complete reaction with apramycin. However, an excessive 
OPA concentration can accelerate the derivative decompo-
sition rate (Stobaugh et al., 1983; Jacobs, Leburg, Madaj, 
1986; Dorresteijn, 1996).
In order to determine the most suitable OPA, another 
stability test was also carried out comprising the deriva-
tization of three apramycin test solutions with OPA in the 
presence of 2-mercaptoacetic acid in such a way that the 
final OPA concentrations were 2.5, 5, 10 and 50 times, 
respectively. This constitutes the concentration needed for 
complete reaction with apramycin, whose concentration 
FIGURE 2 - Graph Area versus Time of formation and 
decomposition of the apramycin-OPA derivative, formed in the 
presence of 2-mercaptoethanol and fluorescence detection, and 
in the presence of mercaptoacetic acid and UV detection.
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FIGURE 3 - Graph Area versus formation and decomposition 
Time of  apramycin-OPA der iva t ive  wi th  d i ffe ren t 
OPA:apramycin concentration ratios.
remained constant. As in the first test, each solution was 
repeatedly injected every 15 minutes from the first 30 
minutes up to 5 hours of reaction. The data obtained were 
plotted on the graph Apramycin Peak Area versus Reaction 
Time. Figure 3 shows a comparison of the graphs.
According to the graph, the most appropriate OPA: 
apramycin concentration ratio was 5:1, a proportion which 
had been previously used. The proportion of 2.5: 1 proved 
unsuitable because it took excessively long to reach the 
maximum formation of the OPA-Apramycin derivative 
(180 minutes). The proportion of 50:1 was also unsuitable 
because the derivative was rapidly decomposed due to 
very high OPA concentration. A solution with an OPA: 
apramycin ratio of 10:1 had similar formation and decay 
behavior for the derivative formed to that with a 5:1 ratio, 
but took longer to reach the maximum formation of the 
derivative.
After these improvements, the conditions adopted 
in this work, hereafter called “nominal method condi-
tions”, were: pre-column OPA derivatization of apramycin 
in the presence of mercaptoacetic acid for 90 minutes 
in water, with light shielding, at room temperature; 
150 mm x 4.6 mm x 4 µm Synergy Hydro C18 column 
at room temperature; mobile phase composed of 
0.005 mol/L sodium octanosulfonate dissolved in a mix-
ture of acetonitrile: water: acetic acid at a ratio of 45:55:2 
(v/v/v) with a flow rate of 1.0 mL/min; injection volume 
of 50 µL; UV detection at 332 nm.
The apramycin test solution and the blank chroma-
togram solution assayed under these optimized conditions 
are shown in Figure 4. Reduced retention time and better 
symmetry of apramycin peak in comparison with that 
obtained under initial conditions are evident. In addition, 
no other peaks interfere with the apramycin peak in the 
blank chromatogram.
FIGURE 4 - Chromatographic profile of apramycin test solution 
(A) and blank solution (B) obtained with nominal method 
conditions after optimization.
Method validation
Validation of the proposed method was performed 
according to the guidelines of the International Conference 
on Harmonization (ICH guidelines, 2006) and the United 
States Pharmacopoeia (USP 32), in order to confirm its 
suitability for the intended purpose.
Method robustness was demonstrated by resistan-
ce to slight alterations in the mobile phase composition 
(acetonitrile proportion and acetic acid added volume), 
the OPA concentration, as well as column batch and tem-
perature. 
The second parameter to be evaluated was selectivi-
ty. As the proposed method was similar to others employed 
in aminoglycoside determination, it was decided to verify 
initially whether the method response to apramycin was 
unique, even in the presence of similar compounds. As 
it was impossible to test apramycin with all the amino-
glycosides, tobramycin was chosen because is the most 
similar to it, and produced by the same microorganism 
strain and nebramycin derivative, and therefore more li-
kely to cause interference. For the test, an apramycin test 
solution, tobramycin test solution and a mixture of both, 
were prepared and derivatized using the established me-
thod conditions. The comparison among chromatograms 
obtained showed that the tobramycin peak did not interfere 
with that of apramycin, with a relative retention of 1.2 and 
resolution of 3.3.
The second step of the selectivity evaluation was to 
verify the possible interference of apramycin degradation 
products. Since their working standards were not availa-
ble, four 100% apramycin working solutions, along with 
four excipient solutions, were submitted to the following 
forced degradation conditions: acid, alkaline hydrolysis, 
oxidation, besides thermal degradation. The chromato-
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grams of apramycin solution obtained from each kind of 
degradation were compared with those of a 100% apra-
mycin working solution (not submitted to degradation) the 
diluent and the placebo solution, as shown in Figure 5. Un-
der the four conditions, no formation of peaks that could 
interfere with the apramycin peak, were observed, only 
some alterations to its area and, in the case of oxidative 
hydrolysis, an absence of it. These occurrences cannot be 
solely due to possible apramycin degradation, but also to 
modifications in the apramycin-OPA reaction conditions, 
resulting in incomplete or non-occurring reaction.
The method linearity was demonstrated in the 
range 0.02 to 0.05 mg/mL of apramycin concentration, 
the calibration curve having a linear equation equal to 
y=132887304.98x + 127223.84 and a good correlation 
coefficient (r = 0.999).
Precision evaluation was done by determination of 
relative standard deviation of six consecutive injections 
of 100% apramycin working solution (intraday precision) 
on three different days (inter-day precision). The low 
intra-day (0.39%) and inter-day (1.09%) values of RSD 
obtained demonstrated good method precision.
Accuracy was demonstrated by the recuperation test, 
on which the average values of 98.5%, 99.0% and 99.3% 
were obtained for the concentration levels of 70%, 100% 
and 130%, respectively. The quantification and detection 
limits of the method were evaluated by signal: noise ratio 
where values found were 0.08 µg/mL and 0.02 µg/mL, 
respectively, thus demonstrating good detectivity.
Apramycin assay by HPLC and turbidimetric 
methods
The final stage of this work was the analysis of three 
batches of apramycin oral soluble powder by the previou-
sly validated proposed HPLC method and by the official 
turbidimetric method, in order to confirm the potency of 
apramycin. Table I shows all results obtained for both 
methods, which comply with the limit of 95% to 105% 
established by the BP 2008.
In relation to the turbidimetric method described by 
the BP 2008, some changes were made concerning the me-
dium and assay design. The British Pharmacopoeia recom-
mends the H medium, but the C medium was used, which 
contains all the constituents (dextrose, tryptone, meat 
extract) besides buffering agents (dibasic and monobasic 
potassium phosphate) plus yeast extract, that enriches the 
medium rendering it more favorable for microbial growth, 
in turn, contributing to more defined and distinct responses 
to the different apramycin concentrations. With regard 
to the design, the British Pharmacopoeia recommends 
the 3X3 design, but 5X1 was employed because more 
concentration levels are used and this design provides a 
FIGURE 5 - Selectivity Evaluation: Comparison among 
chromatographic profiles of 100% apramycin working solution 
(A), diluent (B), placebo solution (C), apramycin solution 
submitted to acid hydrolysis (D), apramycin solution submitted 
to alkaline hydrolysis (E), apramycin solution submitted to 
oxidative degradation (F) and apramycin solution submitted 
to thermal degradation (G). Chromatograms obtained under 
nominal method conditions.
TABLE I - Results of apramycin assay obtained for the three batches of oral soluble powder by the HPLC method and by the official 
turbidimetric assay
Sample
% Apramycin (under sulfate form)
Batch A Batch B Batch C
HPLC Turb. Assay HPLC Turb. Assay HPLC Turb. Assay
1 95.33 98.53 98.73 98.76 102.59 100.38
2 95.64 96.03 97.95 100.43 101.72 101.23
3 96.10 98.76 98.45 98.36 103.72 98.64
Average 95.69 97.77 98.38 98.52 102.68 100.42
RSD* (%) 0.40 1.55 0.40 0.85 0.98 0.79
* - Relative Standard Deviation
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TABLE II - Statistical comparison between apramycin assay by HPLC method and by microbiological method for three batches of 
oral soluble powder
Batch A Batch B Batch C
HPLC Microbiological HPLC Microbiological HPLC Microbiological
Average 95.69 97.77 98.71 98.52 102.68 100.42
Variance 0.15 2.29 0.56 0.71 1.01 0.63
Observations 3 3 3 3 3 3
Hypothesis of average difference 0 0 0
Degrees of Freedom 2 2 2
Stat t (t calculated) -2.420 -0.963 2.180
P(T<=t) bi-caudal 0.137 0.437 0.161
t critical bi-caudal 4.303 4.303 4.303
better estimates of linear equation. Moreover, use of the 
5X1 design allowed apramycin determination of the three 
batches in a single assay.
Both methods were statistically compared, batch 
to batch, by the t test to check the correlation between 
them. As shown in Table II, for each tested batch, tcalculated 
was lower than tcritical, which allows the assertion that 
the obtained averages for each method are equivalent 
to α=0.05. Hence, the HPLC and turbidimetric methods 
can be used interchangeably to assay apramycin in oral 
soluble powder.
Although the turbidimetric assay described by the 
British Pharmacopoeia is the official method for determi-
ning apramycin potency, it has some drawbacks that can 
affect the final result. These include the fact that it does 
not apply to turbid or colored samples; the sample must be 
in solution; it is highly susceptible to time and incubation 
temperature variations, rendering method reproducibility 
hard; while complexity of sample components can cause 
interference in the transmittance reading.
On the other hand, the use of chemical methods in 
antibiotics analysis has been increasing, especially by 
HPLC which, besides providing results faster, also offers 
other indispensable attributes such as sensitivity, specifi-
city, accuracy and precision, which make its employment 
advantageous. Considering these findings, the proposed 
method for determining apramycin in oral soluble powder 
is a valuable and feasible alternative for apramycin deter-
mination that can be applied in quality control analysis 
of oral soluble powder and in other apramycin dosage 
formulations in the future.
CONCLUSION
The LC method proposed for determination of apra-
mycin in oral soluble powder was successfully developed 
and validated, demonstrating robustness, selectivity, line-
arity (in 0.02 ton 0.05 mg/mL range), precision, accuracy 
and good detectivity, therefore proving suitable for its 
intended purpose.
Statistical comparison between the proposed LC me-
thod and the official microbiological turbidimetric method 
by the t test detected no significant difference between the 
two, confirming that the LC method is also reliable and 
suitable for routine analysis of apramycin assay.
REFERENCES
ALBRACHT, J.H. Analysis of gentamicin in raw material and 
pharmaceutical preparations by high performance liquid 
chromatography. J.Chomatogr., v.389, p.306-311, 1987.
BRITISH pharmacopoeia (Veterinary): 2008. London: Her 
Majesty’s Stationery Office, p.38-40, 122-125, 2008.
BRITISH pharmacopoeia. London: Her Majesty’s Stationery 
Office, v.4, p.A95, A323-A329, 2008.
BRITISH pharmacopoeia. London: Her Majesty’s Stationery 
Office, v.4, p.A279-A285, 2000.
CATURLA,  M.C. ;  CUSIDO,  E.  High-performance 
liquid chromatography method for the determination 
of aminoglycosides based on automed pre-column 
derivatization with o-phtalaldehyde. J.Chomatogr., v.593, 
p.69-72, 1992.
CLAES,  P. J . ;  BUSSON,  R;  VANDERHAEGHE H. 
Determintation of the component ratio of commercial 
gentamicins by high performance liquid chromatography 
using pre-column derivatization. J.Chomatogr., v.298, p. 
445-457, 1984.
E. A. B. Antunes, F. R. Lourenço, T. J. A. Pinto268
DORRESTEIJN, R.C., BERWALD, L.G., ZOMER, G., 
GOOIJER, C.D., WIETEN, G. Determination of amino 
acids using o-phthalaldehyde-2-mercaptoethanol 
derivatization – Effect of reaction conditions. J.Chromatogr. 
A, v.724, p.159-167, 1996.
EUROPEAN MEDICINES AGENCY. EMA. Committee for 
Veterinary Medicinal Products. Apramycin. Available 
at: http://www.ema.europa.eu/docs/en_GB/document_
library/Maximum_Residue_Limits_-_Report/2009/11/
WC500010684.pdf Accessed on: 15 out. 2008. 
FABRE, H.; SEKKAT M.; BLANCHIN M. D.; MANDROU 
B. Determination of Aminoglycosides in Pharmaceutical 
F o r m u l a t i o n s  –  I I .  H i g h  P e r f o r m a n c e  L i q u i d 
Chromatography. J. Pharm.Biomed. Anal., v.7, n.12, 
p.1711-1718, 1989.
INTERNATIONAL CONFERENCE ON HARMONIZATION. 
ICH. ICH of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) Q2 (R1). Geneve, 
2006. p.1-13.
ISOHERRANEN N.; SOBACK S. Chromatographic Methods 
for Analysis of Aminoglycoside Antibiotics. J. AOAC Int., 
v.82, n.5, p.1017-1045, 1999.
JACOBS, W.A.; LEBURG, W.; MADAJ, E.J. Stability of 
o-phthalaldehyde-derived isoindoles. Anal. Biochem., 
v.156, n.2, p.334-340, 1986.
MACNEIL, J.D.; ELLIS, R. Regulatory overview of antibiotic 
use in food-producing animals in north america and 
current methods of detection and analysis. In: OKA, H.; 
NAKAZAWA, H.; HARADA, K.; MACNEIL, J.D. (Eds.). 
Chemical analysis for antibiotics used in agriculture. 
Arlington: AOAC International, cap.1, p.2-29, 1995.
MARTINDALE: The complete drug reference. 35.ed. London: 
Pharmaceutical Press, 2007. p.182.
PERZYNSKI ,  S . ;  CANNON,  M. ;  CUNDLIFE,  E . ; 
CHAHWALA, S.B.; DAVIES, J. Effects of Apramycin, 
a novel aminoglycoside antibiotic. Eur. J. Biochem., v.99, 
p.623, 1979.
STEAD, D.A. Current methodologies for the analysis of 
aminoglycosides. J. Chromatogr., B: Biomed. Sci. Appl., 
v.747, n.1/2, p.69-93, 2000.
STOBAUGH, J.F.; REPTA, A.J.;  STERNSON, L.A.; 
GARREN, K.W. Factors affecting the stability of fluorescent 
isoindoles derived from reaction of o-phthalaldehyde and 
hydroxyalkylthiols with primary amines. Anal. Biochem., 
v.135, n.2, p.495-504, 1983.
SWEENEY, D.J.; COLEMAN, M.R. Determination of 
Apramyc in  i n  Swine  K idney  Ti s sue  by  l i qu id 
Chromatography with Fluorescence Detection. J. AOAC 
Int., v.81, n.6, p.1141-1145, 1998.
TATSUTA, K.; AKIMOTO, K.; TAKAHASHI, H.; HAMATSU, 
T.; ANNAKA, M.; KINOSHITA, M. Total synthesis of 
aminoglycoside antibiotics, apramycin and saccharocin 
(KA-5685). Bull. Chem. Soc. Jpn., v.57, p.529-538, 1984.
UNITED States pharmacopoeia. 32.ed. Rockville: United States 
Pharmacopeial Convention, v.2, p.2489, 2009.
UNITED States pharmacopoeia. 32.ed. Rockville: United States 
Pharmacopeial Convention, v.1, p.233-237, p.734-736, 
2009.
WALTON, J.R. Apramycin, a new aminocyclitol antibiotic. J. 
Antimicrob. Chemother., v.4, p.309-313, 1978.
WEIGAND, R.; COOMBES, R.J. Gentamicin determination 
by high performance liquid chromatography. J.Chomatogr., 
v.281, p.381-385, 1983.
ZHANG, L.; WANG, Z.; CHANG, B.; YANG, W. Determination 
of Apramycin in Animal Feeds by Solid-Phase Extraction 
and Liquid Chromatography with Precolumn Derivatization 
and Fluorescence Detection. J. AOAC Int., v.90, n.4, p.885-
891, 2007.
Received for publication on 15st January 2010
Accepted for publication on 01st February 2011
